Mucormycete infection or colonisation: experience of an Australian tertiary referral centre
Mucormycete infection or colonisation: experience of an Australian tertiary referral centre
复制标题
DOI：
10.1111/myc.12467
复制
发表时间：
2016-05
期刊：
影响因子：
4.9
通讯作者：
S. Langford;J. A. Trubiano;S. Saxon;D. Spelman;C. Morrissey
中科院分区：
文献类型：
--
作者：
S. Langford;J. A. Trubiano;S. Saxon;D. Spelman;C. Morrissey
Mucormycosis is associated with significant morbidity and mortality. We reviewed patients with mucormycete isolated at Alfred Health, Australia. A retrospective review of 66 patients with mucormycete(s) identified, between 1 April 2008 and 30 June 2014. Baseline demographic, microbiological, radiological, treatment/outcome data were recorded. Site of isolation was sinopulmonary in 77% and skin/soft tissue in 21%. A total of 32% of cases were proven‐IFD, 12% probable‐IFD and 56% were defined as no‐IFD (or colonisation). Rhizopus spp. was identified in 48%. Comparing probable/proven‐IFD with no‐IFD/colonisation, more patients were postallogeneic stem cell transplantation (28% vs. 0%, P 20 mg daily (24% vs. 5%, P = 0.04). A total of 93% of patients with proven/probable IFD received treatment while 30% of no‐IFD/colonisation were treated. A total of 72% of patients with proven/probable IFD and 92% of those with colonisation had no further mucormycete isolated. Thirty day mortality was higher in the proven/probable‐IFD cohort (24%) compared with no‐IFD/colonisation (3%) (P = 0.02). Mucormycosis remains uncommon, with 56% of cases not associated with clinical infection. Immunosuppressive therapy remains strongly associated with mucormycosis. Mortality remains high in those with proven/probable IFD.
